Initial Mechanism of Action for The Therapeutic Application of Melanocortin Receptor Agonists to Reset Immune Tolerance in EAU10/01/2019 - 06/21/2025 (PI)
Palatin Technologies, Inc.
Study of the potential therapeutic use of Purified Cortrophin Gel for uveitis05/08/2023 - 12/01/2024 (PI)
ANI Pharmaceuticals, Inc.
Projects for the Massachusetts Lions Eye Research Fund07/01/2014 - 08/31/2024 (PI of Sub-Project / SP)
PI:
Stephen P. Christiansen, MDMassachusetts Lions Eye Research Fund, Inc.
Manipulation of Immunity to Treat Uveitis03/01/2020 - 02/29/2024 (PI)
NIH/National Eye Institute5R01EY025961-08
Manipulation of Immunity to Treat Uveitis03/01/2016 - 02/29/2024 (PI)
NIH/National Eye Institute5R01EY025961-04
The role of Wnt signaling in treating glucocorticoid-induced glaucoma09/30/2021 - 07/31/2023 (Subcontract PI)
Trustees of Indiana University NIH NEI5R01EY031700-02
Initial Mechanism of Action for The Therapeutic Application of Melanocortin Receptor Agonists to Suppress EAU06/01/2018 - 12/31/2019 (PI)
Palatin Technologies, Inc.
The MC1R protein palmitoylation in melanoma development09/19/2018 - 11/30/2019 (PI)
NIH/National Cancer Institute5R01CA224432-02
Initial Mechanism Of Action For The Therapeutic Application Of A Melanocortin Receptor Agonists To Attenuate Retinal Damage in Diabetic Retinopathy06/01/2017 - 12/31/2018 (PI)
Palatin Technologies, Inc.
Initial Mechanism Of Action For The Therapeutic Application Of A Melanocortin Receptor Agonists To Supress EAU02/10/2014 - 06/30/2016 (PI)
Palatin Technologies, Inc.